New drug clears psoriasis in clinical trials
About 80 percent of patients with moderate to severe psoriasis saw their disease completely or almost completely cleared with a new drug called ixekizumab, according to three large, long-term clinical trials led by Northwestern Medicine investigator Kenneth Gordon, MD, professor of Dermatology.
The results of these phase III trials were compiled in a paper published in the New England Journal of Medicine.
Click on this link for more information.
